| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg | |||
| Other Sizes |
| ln Vitro |
14-Deoxy-11,12-didehydroandrographolide demonstrated anti-HIV activity with an EC50 of 57 μg/mL in an assay using H9 cell lines.
The compound also showed viricidal activity against herpes simplex virus 1 (HSV-1) without significant cytotoxicity. In RAW 264.7 macrophages transiently transfected with NF-κB reporter plasmids, the compound inhibited NF-κB-dependent transcriptional activation with an IC50 of 17.1 μg/mL. It also inhibited the production of pro-inflammatory cytokines TNF-α (IC50 20.64 μg/mL), IL-6 (IC50 23.6 μg/mL), MIP-2 (IC50 15.03 μg/mL), and nitric oxide (NO, IC50 11.26 μg/mL) in LPS/IFN-γ-stimulated macrophages.[2] |
|---|---|
| ln Vivo |
14-Deoxy-11,12-didehydroandrographolide, isolated from the methanol extract of A. paniculata, significantly reduced mean arterial pressure (MAP) and heart rate in anaesthetized rats after intravenous administration.
It also reduced the beating rate of isolated right atria. The compound showed vasorelaxant effects in isolated rat thoracic aorta, potentially through the activation of nitric oxide synthase (NOS) and guanylyl cyclase, leading to NO release from endothelial cells. The hypotensive effects of the A. paniculata hot water extract are suggested to be partly mediated by this compound, acting on vascular smooth muscle.[2] |
| Cell Assay |
An NF-κB-dependent luciferase reporter assay was used to screen for anti-inflammatory activity. RAW 264.7 macrophages were transiently transfected with NF-κB reporter plasmids. Cells were pretreated with the test compound and then stimulated with LPS (100 ng/mL) and IFN-γ (1000 units/mL). Luciferase activity was measured to assess NF-κB trans-activation inhibition.
For cytokine and NO measurement, the supernatants from the stimulated macrophages were collected. TNF-α, IL-6, and MIP-2 levels were determined using commercial ELISA kits. Nitric oxide production was measured using the Griess assay.[2] |
| Animal Protocol |
The compound's cardiovascular effects were studied in anaesthetized Sprague-Dawley rats. 14-Deoxy-11,12-didehydroandrographolide was administered intravenously, and mean arterial pressure (MAP) and heart rate were monitored.
For studies on isolated tissues, the thoracic aorta and right atria were isolated from rats. The aortic rings were mounted in organ baths containing physiological salt solution, and tension was recorded to assess vasorelaxation. The beating rate of the isolated right atria was also measured.[2] |
| ADME/Pharmacokinetics |
This study investigated the pharmacokinetics of dehydroandrographolide succinate (DAS) after a single intravenous injection of 80, 160, and 320 mg in healthy Chinese volunteers (n=9, crossover design). The drug was administered intravenously in 250 mL of 5% glucose solution over a constant infusion rate for 60 minutes. Within the studied dose range, DAS exhibited nonlinear pharmacokinetic characteristics. The mean maximum plasma concentration (Cmax) for the 80, 160, and 320 mg dose groups was 4.82 mg/L, 12.85 mg/L, and 26.90 mg/L, respectively. The mean time to reach Cmax (Tmax) ranged from 0.94 to 1.0 hours. The mean plasma concentration-time area under the curve (AUC0-12) from 0 to 12 hours was 6.18 mg·L⁻¹·h, 16.95 mg·L⁻¹·h, and 40.65 mg·L⁻¹·h for the 80 mg, 160 mg, and 320 mg dose groups, respectively. The mean elimination half-life (t₁/₂) was approximately 1.51 to 1.89 hours. The mean plasma clearance (CLz) decreased with increasing dose: 13.27 L/h for the 80 mg group, 9.60 L/h for the 160 mg group, and 8.07 L/h for the 320 mg group. The amount of unchanged DAS excreted in urine within 24 hours ranged from 10.1% to 15.5% of the administered dose, with over 90% of the unchanged drug excreted within the first 4 hours. No significant pharmacokinetic differences were observed between men and women. [1]
|
| Toxicity/Toxicokinetics |
DAS injection was well tolerated in healthy volunteers with a single intravenous dose up to 320 mg. One subject reported a minor adverse event (stomach pain) 24 hours after receiving a 320 mg dose; the adverse event resolved spontaneously within 2 hours. No serious or unexpected adverse events occurred. No clinically significant changes were observed in laboratory test values, vital signs, or electrocardiogram parameters. [1]
|
| References |
|
| Additional Infomation |
It has been reported that Andrographis paniculata contains dehydroandrographolide, and there are related data reports. Dehydroandrographolide succinate (DAS) is a derivative extracted from the Chinese herb Andrographis paniculata. Due to its immunostimulatory, anti-infective and anti-inflammatory effects, DAS injection is used clinically in China to treat viral pneumonia and upper respiratory tract infections. This study concludes that the pharmacokinetics of DAS is nonlinear, with the increase in AUC and Cmax slightly higher than the dose ratio, while the clearance rate decreases with increasing dose. The authors suggest that multiple small doses be administered in clinical treatment regimens to maintain effective concentrations and avoid potential drug accumulation. [1] 14-Deoxy-11,12-Didehydroandrographolide is a diterpenoid compound isolated from the medicinal plant Andrographis paniculata. It is an analog of andrographolide, which is the main bioactive component of this plant.
It has been reported that the compound has a variety of pharmacological activities, including immunostimulatory, anti-infective (against HIV and HSV-1), anti-inflammatory (by inhibiting the NF-κB pathway) and anti-atherosclerotic (vasodilatory and hypotensive) effects. It is one of the traditional active ingredients of Andrographis paniculata used to treat infections, inflammation and possible cardiovascular diseases. [2] |
| Molecular Formula |
C20H28O4
|
|---|---|
| Molecular Weight |
332.43
|
| Exact Mass |
332.198
|
| CAS # |
134418-28-3
|
| PubChem CID |
6473762
|
| Appearance |
Off-white to light yellow solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
512.8±50.0 °C at 760 mmHg
|
| Flash Point |
178.3±23.6 °C
|
| Vapour Pressure |
0.0±3.0 mmHg at 25°C
|
| Index of Refraction |
1.584
|
| LogP |
2.97
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
24
|
| Complexity |
605
|
| Defined Atom Stereocenter Count |
5
|
| SMILES |
C[C@@]12CC[C@H]([C@@]([C@H]1CCC(=C)[C@H]2C/C=C/3\C=COC3=O)(C)CO)O
|
| InChi Key |
YIIRVUDGRKEWBV-FZOOCBFYSA-N
|
| InChi Code |
InChI=1S/C20H28O4/c1-13-4-7-16-19(2,10-8-17(22)20(16,3)12-21)15(13)6-5-14-9-11-24-18(14)23/h5,9,11,15-17,21-22H,1,4,6-8,10,12H2,2-3H3/b14-5+/t15-,16+,17-,19+,20+/m1/s1
|
| Chemical Name |
(3E)-3-[2-[(1R,4aS,5R,6R,8aS)-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylidene-3,4,4a,6,7,8-hexahydro-1H-naphthalen-1-yl]ethylidene]furan-2-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~250 mg/mL (~752.04 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (6.26 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (6.26 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (6.26 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.0082 mL | 15.0408 mL | 30.0815 mL | |
| 5 mM | 0.6016 mL | 3.0082 mL | 6.0163 mL | |
| 10 mM | 0.3008 mL | 1.5041 mL | 3.0082 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
